Purple mountain observatory of the chinese academy of sciences, Research institute in Beijing, China

The candidate vaccine, known as DNA-rTV, relies on replication of the virus' DNA to stimulate "effective immunization" against the virus, said Shao Yiming, an HIV researcher at the Chinese Centre for Disease Control and Prevention.According to Shao, this vaccine similar to the one used to prevent smallpox is the first to undergo a second-phase human trial."With significant reduction of virulence, the vaccine will not cause infection in healthy receivers," Shao was quoted as saying by Efe news.Moreover, the vaccine being developed does not contain all segments of the virus but some parts of its genetic material, so that the chances of infection are significantly reduced, the report said.The DNA of the virus will continue replicating after vaccination, thereby stimulating the immune system continuously to produce antibodies, a similar process to the one used by vaccines for other diseases.Most of the HIV vaccines being developed in China and around the world are inactivated vaccines, which do not contain HIV DNA that can replicate, so their effect is not long-lasting.The first phase of testing, started in 2007, proved the "safety" of the vaccine while the second phase will serve to determine the vaccination procedure to be followed in the future, Shao said."Hopefully, the second-phase trial will be completed in the latter half of 2021, and the third-phase clinical trial may start at the end of that year, which will involve thousands of volunteers in a trial to test the effectiveness of the vaccine to protect people against HIV," he added.The research group has already recruited over 130 volunteers and initial work has begun in two Chinese hospitals, one in Beijing and another in Hangzhou in eastern China.Chuang Chuang, head of Hangzhou Sunflower, a non-profit promoting lesbian, gay, bisexual, and transgender (LGBT) rights, told China Daily that over 100 volunteers had already registered with the organization after coming to know about the second phase.There are nearly 1.25 million HIV-positive patients in China, where around 80,000 people contract the disease every year, according to the National Health Commission.( With inputs from IANS )

Purple Mountain Observatory Of The Chinese Academy Of SciencesFOLLOW

Purple mountain observatory of the chinese academy of sciences, Latest News

The informal summit between Chinese President Xi Jinping and Indian Prime Minister Narendra Modi later this year will take the bilateral relations to new heights but at the same time the two countries cannot let "individual" issues hurt their ties, B ...

China and India will have to jointly stand up to counter US "ugly" unilateralist and protectionist trade policies to promote a fair and just economic order, Beijings newly-appointed envoy Sun Weidong to New Delhi has said. ...

US National Security Adviser John Bolton has said China is threatening peace and stability in the Indo-Pacific region by adopting coercive behaviour towards its southeast Asian neighbours. ...

resources, past conversations often centered around fossil fuels and them becoming scarce due to overuse. However, recent conversations have stirred our attention to another natural resource that is available in abundance but is still causing a crisi ...

As Pakist Prime Minister Imran Khan gears up for his first high-level visit to the United States, experts believe that Islamabad is playing a double game in managing affairs between Washington and Beijing -- the two rival economies. ...

China's space lab Tiangong-2 on Friday re-entered the earth's atmosphere, said China Manned Space Agency (CMSA). ...

In a bid to boost cultural exchanges between China and West Bengal, the Chinese consulate in Kolkata is planning to attract more tourists from the Communist nation to the city during the Durga Puja festival this year, a senior diplomat said here on F ...

A group of Chinese scientists will start trialing a long-lasting human immunodeficiency virus (HIV) vaccine on 160 volunteers, the first time that such a vaccine has reached a second-phase human trial, the official newspaper China Daily reported on F ...